DE60137364D1 - Kristalline formen von atorvastatin - Google Patents

Kristalline formen von atorvastatin

Info

Publication number
DE60137364D1
DE60137364D1 DE60137364T DE60137364T DE60137364D1 DE 60137364 D1 DE60137364 D1 DE 60137364D1 DE 60137364 T DE60137364 T DE 60137364T DE 60137364 T DE60137364 T DE 60137364T DE 60137364 D1 DE60137364 D1 DE 60137364D1
Authority
DE
Germany
Prior art keywords
crystalline forms
atorvastatin
directed
present
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60137364T
Other languages
English (en)
Inventor
Der Schaaf Paul Adriaan Van
Fritz Blatter
Martin Szelagiewicz
Kai-Uwe Schoening
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of DE60137364D1 publication Critical patent/DE60137364D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60137364T 2000-12-27 2001-12-19 Kristalline formen von atorvastatin Expired - Fee Related DE60137364D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00811249 2000-12-27
PCT/EP2001/015012 WO2002051804A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Publications (1)

Publication Number Publication Date
DE60137364D1 true DE60137364D1 (de) 2009-02-26

Family

ID=8175112

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137364T Expired - Fee Related DE60137364D1 (de) 2000-12-27 2001-12-19 Kristalline formen von atorvastatin

Country Status (23)

Country Link
US (4) US7538136B2 (de)
EP (2) EP2000461A1 (de)
JP (2) JP2004516311A (de)
KR (1) KR100790766B1 (de)
CN (1) CN1273449C (de)
AT (1) ATE420070T1 (de)
AU (1) AU2002224952B2 (de)
CA (7) CA2622477A1 (de)
CZ (1) CZ20032019A3 (de)
DE (1) DE60137364D1 (de)
ES (1) ES2319870T3 (de)
HR (1) HRP20030607A2 (de)
HU (1) HUP0302519A3 (de)
IL (1) IL156280A0 (de)
IS (1) IS6859A (de)
MX (1) MXPA03005879A (de)
NO (1) NO20032758D0 (de)
NZ (1) NZ527048A (de)
PL (1) PL365312A1 (de)
PT (1) PT1345896E (de)
SK (1) SK9532003A3 (de)
WO (1) WO2002051804A1 (de)
ZA (1) ZA200304297B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (de) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatin hemi-kalzium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) * 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
UA74075C2 (en) 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
JP2005500351A (ja) * 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
NZ529913A (en) * 2001-08-16 2005-03-24 Teva Pharma Processes for preparing calcium salt forms of statins
WO2003018547A2 (en) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
EP1480950A4 (de) * 2002-02-15 2005-05-18 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
CA2475123A1 (en) 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
EP1572643A2 (de) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Kristalline form f von atorvastatin hemi calcium salz
EP1424324A1 (de) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Kristalline Form F von Atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
CA2627940A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
WO2006008886A1 (ja) 2004-06-11 2006-01-26 Ginkgo Biomedical Research Institute Co., Ltd. インターフェロン産生細胞の活性調節剤
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
EP1771412A2 (de) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Kristalline formen von [r-(r*)]-2-(4-fluorphenyl)-beta,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure-calciumsalz (2:1)
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
WO2006106372A1 (en) * 2005-04-08 2006-10-12 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New crystalline atorvastatin hemicalcium salt polymorph form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
TW200745026A (en) * 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
BRPI0702900A2 (pt) * 2006-06-28 2011-03-15 Teva Pharma formas cristalinas da atorvastatina
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
JP2019167295A (ja) * 2016-07-04 2019-10-03 ゼリア新薬工業株式会社 １，５−ベンゾジアゼピン化合物カルシウム塩の製造法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848705T1 (en) 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
ES2349364T3 (es) * 1999-11-17 2010-12-30 Teva Pharmaceutical Industries, Ltd. Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica.
AU780247B2 (en) 1999-12-17 2005-03-10 Pfizer Science And Technology Ireland Limited A process for producing crystalline atorvastatin calcium
EP1332130A4 (de) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatin hemi-kalzium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) * 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
UA74075C2 (en) * 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
JP2005500351A (ja) * 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム

Also Published As

Publication number Publication date
HRP20030607A2 (en) 2005-06-30
US20090281162A1 (en) 2009-11-12
EP1345896A1 (de) 2003-09-24
US20060205805A1 (en) 2006-09-14
IS6859A (is) 2003-06-24
CA2623599A1 (en) 2002-07-04
CA2622697A1 (en) 2002-07-04
CA2622477A1 (en) 2002-07-04
PT1345896E (pt) 2009-02-19
JP2009221216A (ja) 2009-10-01
MXPA03005879A (es) 2003-09-10
IL156280A0 (en) 2004-01-04
US20030114686A1 (en) 2003-06-19
CA2626317A1 (en) 2002-07-04
ATE420070T1 (de) 2009-01-15
CA2431068A1 (en) 2002-07-04
SK9532003A3 (en) 2004-04-06
CA2431068C (en) 2008-06-10
CN1273449C (zh) 2006-09-06
NZ527048A (en) 2004-12-24
PL365312A1 (en) 2004-12-27
EP2000461A1 (de) 2008-12-10
KR20030064880A (ko) 2003-08-02
EP1345896B1 (de) 2009-01-07
US7538136B2 (en) 2009-05-26
WO2002051804A1 (en) 2002-07-04
CN1483022A (zh) 2004-03-17
ES2319870T3 (es) 2009-05-14
NO20032758L (no) 2003-06-17
KR100790766B1 (ko) 2008-01-03
CA2622727A1 (en) 2002-07-04
JP2004516311A (ja) 2004-06-03
CA2623600A1 (en) 2002-07-04
NO20032758D0 (no) 2003-06-17
HUP0302519A3 (en) 2008-10-28
HUP0302519A2 (hu) 2003-12-29
AU2002224952B2 (en) 2007-04-05
US20040220255A1 (en) 2004-11-04
CZ20032019A3 (cs) 2003-10-15
ZA200304297B (en) 2004-08-16

Similar Documents

Publication Publication Date Title
ATE420070T1 (de) Kristalline formen von atorvastatin
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
DE60044884D1 (de) Verfahren zur Herstellung einer polymorphen Form von Atorvastatin calcium
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
DE60009511D1 (de) Nematizide trifluorbutene
DE60226044D1 (de) Kristalline formen von fluvastatin-natrium
EA200200940A1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
EA200300579A1 (ru) Соединение лактама
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
DE60129442D1 (de) Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60213541D1 (de) Discodermolid-Analoga und ihre pharmazeutische Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee